← All sources
Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of 29 RCTs (2,396 participants) across OA, RA, AS, JIA, and gout/hyperuricemia: curcumin or Curcuma longa extracts (about 120–1500 mg/day for 4–36 weeks) were reported as safe and associated with improved pain and inflammation severity in narrative quantitative synthesis, with authors warning of low RCT quality.
Design
- Systematic review + meta-analysis; RCTs across PubMed, Cochrane, CNKI, etc.
- Included: 29 RCTs; 2396 participants; 5 arthritis categories (OA, RA, AS, JIA, gout/hyperuricemia)
- Intervention: curcumin or Curcuma longa extract (120–1500 mg/day; 4–36 weeks)
Authors' quantitative narrative
- Safety: authors report no serious safety signals pooled across included trials
- Symptoms / inflammation: authors report directional improvements in pain and inflammatory severity measures with low overall trial quality and small-study limitations
Evidence hygiene
- Heterogeneous arthritis diagnoses and formulation/bioavailability differences—avoid treating as one interchangeable "curcumin pill."
Publication
Zeng L, Yu G, Shu W, et al. Front Immunol. 2022 Jul 22;13:891822. PMID 35935936.
Outcomes
- 29 RCTs (n=2396) across OA, RA, AS, JIA, and gout/hyperuricemia: authors report curcumin/Curcuma longa extract was safe and improved pain and inflammation severity versus comparators in pooled narrative, with low-quality RCT caveats.